Be it the value, growth, or dividend style of investing – the pharma industry has catered to all. The pharma index returned a 30% CAGR from 2009 to 2016. Undoubtedly, you would've earned higher returns if you invested in the best pharma stocks at the time.
However, the industry has been plagued with troubles for the last four years. Be it the US FDA approval problems, drug price controls, unsuccessful and expensive acquisitions and as yet unfruitful R&D – the industry had to face it all. As you can expect pharma companies share prices have been subdued during this time.
The Covid-19 crisis has again spiked up interest of investors in the pharma industry. There are expectations that both government and private healthcare spending will increase post this pandemic.
If you're planning to invest in the pharma industry, Moneyworks4me has a detailed list of the top pharma companies in India including the top 10 by market cap in the pharma stocks list outlined below.
The companies mentioned in the below pharma share list can be sorted based on various ratios including price to earnings (P/E) and price to book value (P/BV). The colour coded 10-year X-Ray can help you choose to identify the good companies from the not so good ones.
Presently, India is the largest provider of generic medicines, occupying a market share of 20 percent with respect to global supply by volume and fulfils nearly 60 percent of global demand for vaccines. Indian pharmaceutical companies even supply nearly 80 percent of antiretroviral drugs (used in combating AIDS) in the international markets.
There are several benefits of investing in pharma companies:
Long-term profitability – Pharma companies can be attractive to long-term investors in spite of the volatility. The ever rising industry size and healthcare becoming a critical part of life, investors can make good returns if they invest at the right time.
Exponential growth – Being the evolving industry that it is, innovation, scientific breakthroughs, and technological advances can bring in exponential growth for many pharma companies.